Overview

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

A Phase 1, open-label, single-dose study to determine the safety and pharmacokinetics of ORAvance (ceftibuten/xeruborbactam oral prodrug [QPX7831]) in participants with renal impairment

Phase:

Phase 1

Details

Lead Sponsor:

Qpex Biopharma, Inc.

Collaborators:

Biomedical Advanced Research and Development Authority
Shionogi Inc.

Treatments:

Ceftibuten